We regularly announce Chinese outbound investment opportunities via our webpage. All listed investor portfolios represent direct requests from corporate management teams and/or their dedicated investment arms in China. Please contact us in relation to specific advertised opportunities.

 

Big Data / AI in Health Diagnostics (R&D / Investment)

11th Aug 17 - Profile I86P1

A listed Chinese pharmaceutical company is launching their strategic vision aimed at leveraging the power of ‘Artificial Intelligence (AI) / Big Data' in personalised medicine. The execution will combine the strengths of an external partner company specialising in AI / Big Data, alongside their own cache of diagnostics data built internally for patient populations treated with Traditional Chinese herbal Medicine (TCM). Diabetes is one key target therapy area, both for early onset pre-diagnosis, and lifelong disease management. To this end, they seek an R&D partner / potential investment target with familiarity in applying AI / Big Data to diagnostic challenges in metabolic medicine.

To join this strategic vision, candidate partners will likely hold the following track record:

  • a B2B SaaS business model,
  • a portfolio of in-market software products,
  • core capabilities in AI / Big Data with a focus on health diagnostics.

Analytical Instrument / Industry 4.0 (Investment / M&A)

13th Aug 17 - Profile I86M4

A China-listed leader in the manufacturing of bench top laboratory analytical instruments. Their strategic vision is international growth via product diversification and investment in differentiated high-end analytical instruments in pharmaceuticals, water, fragrances, VOC gases, and food & drink. They seek to make outbound investment and M&A in niche UK-EU industrial instrumentation SMEs, with a focus on HPLC separation chromatography. The partner will benefit from the resources of a China company with a global footprint, established sales channels worldwide, with the potential to scale manufacturing.

 
To join this strategic vision, candidate partners will likely hold the following track record:
  • an approved in-market product portfolio of bench top instrumentation (HPLC-related preferred),
  • based on a competitive market-leading molecular detection technology,
  • a production operation that would benefit from the synergies offered by the China market.

Cancer IVD Diagnostic Reagents  (R&D / Investment)

13th Aug 17 - Profile I86P3

A major China-listed manufacturer of chemical reagents is accelerating their focus on in vitro diagnostics (IVD) for the large-scale manufacture of detection assay components for life threatening diseases such as cancer. Their execution of this strategic vision will combine the strengths of an external partner company specialising in lab-based IVD diagnostic reagents, alongside their own large scale manufacturing & retail capabilities serving the China market.

To join this strategic vision, candidate partners will likely hold the following track record:

  • an innovative leader in IVD diagnostic probes (e.g. brain, skin, colon, & prostate cancers),
  • a suite of in-market CE or FDA-marked products,
  • products sold worldwide (ex-China) and/or show special alignment with Chinese market.

 Cardiovascular Assets & Stent Medtech (R&D / Investment)

14th Sep 17 - Profile I86P4

A major China-listed small molecule drug manufacturer is accelerating their R&D focus across both therapeutics and medical devices in the area of cardiovascular disease. The company is principally engaged in the GMP manufacture, R&D, and retail of chemical APIs and premium prescription drugs. Together with their subsidiaries, they possess a track record in developing drug platforms, as well as Class III cardiovascular stent products for keyhole surgery. Beyond cardiovascular, they are also active across anti-infectives, oncology, and type 1 diabetes.

To join this strategic vision, candidate partners will be:

  • Developing cardiovascular drug assets (pre-clinical to Phase II).
  • Seeking investment and/or co-development for commercialisation.
  • Possess cardiovascular medtech products (preferably stents) at post-PoC stage.

Blood purification & Kidney Dialysis (Distribution / M&A)

1st Oct 17 - Profile I86M5

A major China-listed manufacturer and retailer of high quality hemoperfusion adsorbent cartridges and blood purification machines, is building on its strong domestic growth via outbound partnerships. Its recent minority/majority acquisitions (at 30-100 million RMB each) served to broaden its domestic coverage while consolidating its leading position in blood purification. Now leveraging its 80% market share among China’s leading hospitals, with distribution channels across 31 of China’s 32 provinces, it aims nurture China market entry of competitive overseas products in dialysis and blood purification requiring domestic support across regulatory, production, and sales.

To join this strategic vision, candidate partners will be:

  • A differentiated leader in dialysis and/or blood purification in your home market.
  • With products covering chemicals, clinical consumables, or portable equipment.
  • Seeking clinical regulatory approval and/or product launch in China.